OTCMKTS:DSNKY Daiichi Sankyo (DSNKY) Stock Price, News & Analysis $33.10 -0.80 (-2.36%) (As of 09/27/2024 08:52 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort Interest About Daiichi Sankyo Stock (OTCMKTS:DSNKY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$32.89▼$34.0850-Day Range$32.74▼$42.0352-Week Range$23.72▼$42.48Volume39,100 shsAverage Volume118,563 shsMarket CapitalizationN/AP/E Ratio0.29Dividend Yield67.88%Price TargetN/AConsensus RatingN/A Company OverviewDaiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.Read More… NOTICE: You have until Tuesday, November 19th (Ad)On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...Click here for the ticker >>> Daiichi Sankyo Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks27th Percentile Overall ScoreDSNKY MarketRank™: Daiichi Sankyo scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Daiichi Sankyo.Read more about Daiichi Sankyo's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Daiichi Sankyo is 0.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.55.Price to Earnings Ratio vs. SectorThe P/E ratio of Daiichi Sankyo is 0.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.84. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares ShortedShort Interest Ratio / Days to CoverDaiichi Sankyo has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daiichi Sankyo has recently decreased by 66.11%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDaiichi Sankyo pays a meaningful dividend of 3.12%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthDaiichi Sankyo does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Daiichi Sankyo is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Daiichi Sankyo's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverDaiichi Sankyo has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daiichi Sankyo has recently decreased by 66.11%, indicating that investor sentiment is improving significantly. News and Social Media1.3 / 5News SentimentN/A News SentimentDaiichi Sankyo has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Daiichi Sankyo this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Daiichi Sankyo insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Daiichi Sankyo is held by institutions.Read more about Daiichi Sankyo's insider trading history. DSNKY Stock News HeadlinesIs Merck Stock Undervalued After Its Colossal Earnings Growth? (DSNKY)Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?September 13, 2024 | marketbeat.comDaiichi Sankyo Co (OTC:DSNKY) Stock Quotes, Forecast and News SummarySeptember 18, 2024 | benzinga.comIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used by EVERY single AI company on the planet... AMD, NVIDIA, META... none of these companies could exist without this firm.September 30, 2024 | Behind the Markets (Ad)Daiichi Sankyo: Showing No Signs Of Slowing Down ADC DominanceSeptember 18, 2024 | seekingalpha.comDaiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 StudySeptember 17, 2024 | markets.businessinsider.comAstraZeneca, Roche cut at Deutsche after trial readouts for key drugsSeptember 13, 2024 | seekingalpha.comAstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming DataSeptember 12, 2024 | seekingalpha.comDaiichi Sankyo Plunges on Mixed Trial Result of Lung Cancer DrugSeptember 10, 2024 | bloomberg.comSee More Headlines DSNKY Stock Analysis - Frequently Asked Questions How have DSNKY shares performed this year? Daiichi Sankyo's stock was trading at $27.35 at the start of the year. Since then, DSNKY shares have increased by 21.0% and is now trading at $33.10. View the best growth stocks for 2024 here. How do I buy shares of Daiichi Sankyo? Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:DSNKY CUSIPN/A CIKN/A Webwww.daiichisankyo.com Phone(136) 225-1111FaxN/AEmployees17,435Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.29 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A This page (OTCMKTS:DSNKY) was last updated on 9/30/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's righ...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Hua...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Daiichi Sankyo Company, Limited You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Daiichi Sankyo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.